Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab and Lenalidomide in R/R Mantle Cell Lymphoma
NCT06192888Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Proportion of participants who successfully receive glofitamab at 1 year. Started Jan 2024; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06192888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192888.